BRAF V600E mutation was positively correlated with the expression of TIM3 in both CRC cells and tumor-infiltrating lymphocytes (TILs) [13] as well as the expression of PD-L1 in tumor cells [14], suggesting that it might act as an indicator of ICI treatment efficacy in mismatch repair-deficiency (dMMR) CRC [15]. The gene discussed is HAVCR2; the disease is neoplasm.